(0.23%) 5 118.00 points
(0.06%) 38 748 points
(0.67%) 17 725 points
(0.10%) $83.44
(0.22%) $1.816
(-0.30%) $2 335.10
(0.10%) $27.39
(0.14%) $924.10
(0.16%) $0.936
(0.15%) $10.92
(0.14%) $0.804
(-0.71%) $92.53
Quarter results today
(amc 2024-04-24)
Expected move: +/- 3.57%
@ $91.96
Issued: 23 Apr 2024 @ 14:56
Return: 0.11%
Previous signal: Apr 23 - 09:30
Previous signal:
Return: 2.14 %
Live Chart Being Loaded With Signals
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...
Stats | |
---|---|
Today's Volume | 1.27M |
Average Volume | 1.40M |
Market Cap | 17.47B |
EPS | $0 ( 2024-02-22 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 105.82 |
ATR14 | $2.23 (2.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Bienaime Jean Jacques | Buy | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
INSIDER POWER |
---|
25.85 |
Last 93 transactions |
Buy: 972 265 | Sell: 563 201 |
Volume Correlation
Biomarin Pharmaceutical Correlation
10 Most Positive Correlations | |
---|---|
MMAC | 0.923 |
RMRM | 0.916 |
FREQ | 0.89 |
ABST | 0.889 |
IMPL | 0.889 |
SGBX | 0.887 |
TTOO | 0.887 |
INFI | 0.885 |
SBBP | 0.884 |
CFV | 0.884 |
10 Most Negative Correlations | |
---|---|
APOP | -0.956 |
ICON | -0.907 |
RDUS | -0.893 |
MIND | -0.88 |
TRMD | -0.879 |
WRLD | -0.878 |
SYKE | -0.875 |
SOUN | -0.873 |
MGTX | -0.873 |
FEYE | -0.869 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biomarin Pharmaceutical Correlation - Currency/Commodity
Biomarin Pharmaceutical Financials
Annual | 2023 |
Revenue: | $2.42B |
Gross Profit: | $1.84B (76.15 %) |
EPS: | $0.890 |
Q4 | 2023 |
Revenue: | $646.21M |
Gross Profit: | $510.73M (79.03 %) |
EPS: | $0.110 |
Q3 | 2023 |
Revenue: | $585.97M |
Gross Profit: | $445.54M (76.04 %) |
EPS: | $0.210 |
Q2 | 2023 |
Revenue: | $594.60M |
Gross Profit: | $450.92M (75.84 %) |
EPS: | $0.300 |
Financial Reports:
No articles found.
Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators